Detail akcie Eagle Pharm online

Business Summary: Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Eagle Pharmaceuticals Inc revenues decreased 31% to $131M. Net income decreased 68% to $10.9M. Revenues reflect Product sales decrease of 36% to $89.2M, Royalty revenue decrease of 18% to $41.7M. Net income also reflects Selling, general and administrative increase of 53% to $48M (expense), Research and development - Balancing val increase of 65% to $17.9M (expense), IE on Capital Financing.